PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-552.87%
Negative operating income growth while RVPH is at 7.11%. Joel Greenblatt would press for urgent turnaround measures.
-675.86%
Negative net income growth while RVPH stands at 5.90%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-2175.00%
Negative EPS growth while RVPH is at 7.69%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-2175.00%
Negative diluted EPS growth while RVPH is at 7.69%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-66.67%
Share reduction while RVPH is at 2.47%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-66.67%
Reduced diluted shares while RVPH is at 2.47%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
18.86%
OCF growth under 50% of RVPH's 38.83%. Michael Burry might suspect questionable revenue recognition or rising costs.
18.86%
FCF growth under 50% of RVPH's 38.83%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-262.10%
We have a declining book value while RVPH shows 89.95%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
43.72%
We have some new debt while RVPH reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.